EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study

Tanushree Haldar iD, Mark Kvale iD, Jia Yang iD, Michael P Douglas iD, Willow Coyote-Maetas iD, Linda Kachuri iD, John S Witte iD, Carlos Iribarren, Marisa W Medina iD, Ronald M Krauss iD, Sook Wah Yee iD, Akinyemi Oni-Orisan iD

Clinical Pharmacology & Therapeutics · 2025-06 · 117 (6) · 1696-1705

DOI: 10.1002/cpt.3624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.03.2025. Verfasst von Tanushree Haldar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Liver-Specific Organic Anion Transporter 1, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Bilirubin, Black People. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHGRI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statin pharmacogenetic implementation guidelines are derived from evidence of primarily Eurocentrically biased study populations. Functional SLCO1B1 variants that are rare in these study populations have not been equitably investigated and are thus missing from guidelines. The objective of this precision medicine health equity study was to determine the clinical validity of understudied candidate functional SLCO1B1 variants common in people with 1,000 Genomes sub‐Saharan African superpopulation (1KG‐AFR‐like) genetic similarity. We conducted our analyses using the real‐world evidence of participants from three large, electronic health record‐linked biobanks. We used bilirubin levels (as an endogenous substrate of organic anion transporting polypeptide [OATP1B1] function) and severe statin‐induced myotoxicity phenotypes. Loss‐of‐function splice variant rs77271279 ( P = 1.1 × 10 −17 ) had the strongest association with elevated total bilirubin levels in Black participants (mean 84% AFR‐like genetic similarity) followed by missense variant rs59502379 ( P = 7.4 × 10 −12 ) then missense variant rs4149056 ( P = 6.0 × 10 −5 ). In an exploratory subset of the Black study population who used statins ( n = 77 severe statin‐induced myotoxicity cases), rs59502379 (odds ratio [OR] = 2.85, 95% confidence interval [CI] 1.08–7.52), but not rs77271279 (OR = 1.75, 95% CI 0.62–4.73) was associated with myotoxicity. Sensitivity analyses in participants with >5% AFR‐like genetic similarity corroborated these findings. For white participants, rs77271279 and rs59502379 were rare precluding subsequent analyses. Our findings highlight the clinical relevance for understudied SLCO1B1 variants on pharmacogenetic testing panels with a potential immediate impact on reducing the risk of severe statin‐induced myotoxicity primarily in Black patients, a group historically excluded from genomic research. Future studies require larger statin user study populations with less heterogeneity by statin type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver-Specific Organic Anion Transporter 1Hydroxymethylglutaryl-CoA Reductase InhibitorsBilirubinBlack PeoplePrecision MedicineHealth EquityMuscular DiseasesHumansMaleFemaleMiddle AgedAgedAfrica South of the SaharaAdultPolymorphism, Single NucleotidePhenotype

Substanzen

Liver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsBilirubin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
  • Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA.
  • Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
  • Quantitative Biosciences Institute, University of California San Francisco, San Francisco, California, USA.
  • Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.
  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Tanushree Haldar, Mark Kvale, Jia Yang, Michael P Douglas, Willow Coyote-Maetas, Linda Kachuri, John S Witte, Marisa W Medina, Ronald M Krauss, Sook Wah Yee, Akinyemi Oni-Orisan

Förderung

  • NCI NIH HHS
  • NHGRI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Haldar, T., Kvale, M., Yang, J., Douglas, M. P., Coyote-Maetas, W., Kachuri, L., Witte, J. S., Iribarren, C., Medina, M. W., Krauss, R. M., Yee, S. W., & Oni-Orisan, A. (2025). SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study. Clinical Pharmacology & Therapeutics, 117(6), 1696-1705. https://doi.org/10.1002/cpt.3624

Vancouver

Haldar T, Kvale M, Yang J, Douglas MP, Coyote-Maetas W, Kachuri L, et al. SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study. Clinical Pharmacology & Therapeutics. 2025;117(6):1696-1705. doi:10.1002/cpt.3624

BibTeX
@article{Haldar2025,
  author = {Haldar, Tanushree and Kvale, Mark and Yang, Jia and Douglas, Michael P and Coyote-Maetas, Willow and Kachuri, Linda and Witte, John S and Iribarren, Carlos and Medina, Marisa W and Krauss, Ronald M and Yee, Sook Wah and Oni-Orisan, Akinyemi},
  title = {SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {6},
  pages = {1696--1705},
  doi = {10.1002/cpt.3624}
}
Kostenlos starten →